Compare Fidelity National Information Servcs Inc (FIS) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Recursion Pharmaceuticals Inc — how do they compare? Fidelity National Information Servcs Inc trades at $42.62 (market cap $21.24B), while Recursion Pharmaceuticals Inc trades at $3.01 (market cap $1.75B). The key difference: Fidelity National Information Servcs Inc is far larger — about 12.1× Recursion Pharmaceuticals Inc's market cap, and Fidelity National Information Servcs Inc pays a 4.09% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| FIS | RXRX | |
|---|---|---|
Market Cap | $21.24B | $1.75B |
Sector | Technology | Health |
52-Week High | $81.94 | $6.79 |
52-Week Low | $37.72 | $2.84 |
Enterprise Value | $41.63B | $1.17B |
Dividend Yield | 4.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $42.02, up 3.54% today, with a bearish technical signal but strong analyst support. The company shows improving fundamentals with Q1 2026 EPS beating expectations and a consensus price target of $52.57. Recent news highlights innovation in AI and cloud banking, though cash flow trends and debt levels warrant monitoring.
The outlook is cautiously optimistic with potential upside from earnings growth and strategic initiatives, balanced by risks from competitive pressures and financial leverage. Investor sentiment is positive driven by analyst buy ratings and recent business wins, but volatility may persist near-term.
Recursion Pharmaceuticals (RXRX) trades at $3.07, down 8.08% in the last session, reflecting ongoing investor concerns about its financial performance. The stock shows a bearish technical signal with moving averages indicating selling pressure, while the company continues to report significant losses with a net income margin of -851.51% for 2025. Recent earnings have consistently beaten expectations, and analyst sentiment remains mixed with a consensus price target of $7.83 representing substantial upside potential from current levels.
The outlook for RXRX hinges on its ability to translate its AI-driven drug discovery platform into sustainable revenue growth and eventual profitability. While the company maintains analyst support and strong institutional backing, significant execution risks remain given its substantial cash burn and negative profitability metrics. The stock presents a high-risk, high-reward opportunity for investors willing to bet on the company's long-term technology potential despite current financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
